Literature DB >> 22963622

The role of a disturbed arginine/NO metabolism in the onset of cancer cachexia: a working hypothesis.

N Buijs1, J Luttikhold, A P J Houdijk, P A M van Leeuwen.   

Abstract

Cancer cachexia is a complex catabolic state in patients with a malignancy, associated with increased morbidity and mortality. This syndrome is characterized by a redistribution of the body's protein content and a subsequent muscle wasting. The aetiology of this syndrome seems multifactorial, but remains unclear. It is suggested that this catabolic state occurs in response to the alterations in immune interactions between tumor and host. The amino acid arginine and its derivate nitric oxide (NO) play various roles in anti-tumor immune response and the body's homeostasis. Glutamine is the precursor for arginine de novo synthesis and the most abundant amino acid in the body, mainly stored in skeletal muscle. Tumors develop a protection mechanism against the specific anti-tumor attack of the immune system by recruiting myeloid derived suppressor cells (MDSC). The MDSC deplete arginine levels and disturb NO production. We here hypothesize that the perturbation of the arginine/NO metabolism plays a significant role in the aetiology of cancer cachexia. Arginine/ NO metabolism is disturbed in patients with cancer. The body will try to correct this perturbation by mobilizing arginine and glutamine from muscles. The decreased arginine levels and the disturbed NO production activate several cascades, which in turn inhibit protein synthesis and promote proteolysis, leading to cachexia. Cachexia remains one of the most frequent and damaging opportunistic syndromes in cancer patients. In this review we will elaborate on a new hypothesised concept and the underlying mechanisms of this syndrome. New studies are essential to ground this hypothesis and to develop interventions to break through the pathological mechanisms underlying cachexia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963622     DOI: 10.2174/092986712803833290

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  Arginine-supplemented enteral nutrition.

Authors:  Jutta Huebner; Ralph Muecke
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-13       Impact factor: 4.553

2.  Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

Authors:  Pauline L de Goeje; Koen Bezemer; Marlies E Heuvers; Anne-Marie C Dingemans; Harry Jm Groen; Egbert F Smit; Henk C Hoogsteden; Rudi W Hendriks; Joachim Gjv Aerts; Joost Pjj Hegmans
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

3.  Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Authors:  Francis Mussai; Sharon Egan; Joseph Higginbotham-Jones; Tracey Perry; Andrew Beggs; Elena Odintsova; Justin Loke; Guy Pratt; Kin Pong U; Anthony Lo; Margaret Ng; Pamela Kearns; Paul Cheng; Carmela De Santo
Journal:  Blood       Date:  2015-02-20       Impact factor: 22.113

4.  Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy.

Authors:  Michael R Deyhle; Chandler S Callaway; Daria Neyroud; Andrew C D'Lugos; Sarah M Judge; Andrew R Judge
Journal:  Cells       Date:  2022-06-10       Impact factor: 7.666

Review 5.  The Janus-Faced Role of Antioxidants in Cancer Cachexia: New Insights on the Established Concepts.

Authors:  Mohamad Assi; Amélie Rébillard
Journal:  Oxid Med Cell Longev       Date:  2016-08-24       Impact factor: 6.543

6.  C57BL/6N Mice Are More Resistant to Ehrlich Ascites Tumors Than C57BL/6J Mice: The Role of Macrophage Nitric Oxide.

Authors:  Sergey Kalish; Svetlana Lyamina; Svetlana Chausova; Lada Kochetova; Yuri Malyshev; Eugenia Manukhina; Igor Malyshev
Journal:  Med Sci Monit Basic Res       Date:  2015-10-20

7.  Metabolic profiling of presymptomatic Huntington's disease sheep reveals novel biomarkers.

Authors:  Debra J Skene; Benita Middleton; Cara K Fraser; Jeroen L A Pennings; Timothy R Kuchel; Skye R Rudiger; C Simon Bawden; A Jennifer Morton
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

8.  Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy.

Authors:  Dilyara Radikovna Kaidarova; Mikhail Valeryevich Kopp; Vadim S Pokrovsky; Maia Dzhugashvili; Zhanna Mukhataevna Akimzhanova; Ramil Zufarovich Abdrakhmanov; Elena Nikolaevna Babich; Evgeniy Viktorovich Bilan; Anton Valeryevich Byakhov; Sergey Nikolaevich Gurov; Irina Albertovna Koroleva; Anastasiia Sergeevna Mochalova; Svetlana Sergeevna Povaga; Maxim Vladimirovich Raigorodsky; Arthur Sidorovich Saifullin; Eduardo Sanz; Fedor Igorevich Petrovskiy
Journal:  Oncol Lett       Date:  2019-09-13       Impact factor: 2.967

Review 9.  Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.

Authors:  Yufei Wang; Anna Jia; Yujing Bi; Yuexin Wang; Guangwei Liu
Journal:  Cells       Date:  2020-04-18       Impact factor: 6.600

10.  Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

Authors:  Francis Mussai; Sharon Egan; Stuart Hunter; Hannah Webber; Jonathan Fisher; Rachel Wheat; Carmel McConville; Yordan Sbirkov; Kate Wheeler; Gavin Bendle; Kevin Petrie; John Anderson; Louis Chesler; Carmela De Santo
Journal:  Cancer Res       Date:  2015-06-08       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.